This study aimed to investigate the efficacy and safety of re-immunotherapy with nivolumab (anti-PD-1 antibody) plus ipilimumab (anti-CTLA-4 antibody) in patients with advanced NSCLC previously treated with anti-PD-1 and/or anti-PD-L1 antibodies. Here, CTLA4 is linked to non-small cell lung carcinoma.